CXCL5-mediated accumulation of SiglecF(high) neutrophils in lung tumor tissues impairs CD8 T cell responses and limits the efficacy of PD-L1 checkpoint blockade.

Francesca SIMONCELLO, Cellular Immunology laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.

A complex network of neutrophil states accumulates in tumor tissues, shaping cancer evolution and limiting the efficacy of immunotherapy. The capacity of specific neutrophil subsets to interfere with spontaneous and therapy-induced anti-cancer T cell responses is, however, poorly understood. In our laboratory, we used a genome editing approach to investigate the role of the cancer-derived C-X-C motif chemokine 5 (CXCL5) in accumulation of tumor associated neutrophils (TANs) in a model of immunogenic lung adenocarcinoma. Focusing on a subset of TANs expressing the lectin SiglecF, I will present how these cells impair tumor specific T cell responses and affect the efficacy of PD-L1 checkpoint blockade. Targeting the CXCL5-neutrophils axis may provide a way to improve the already existent lung cancer immunotherapies.

L’oratrice ne pouvant se déplacer en raison de la pandémie, le séminaire de ce mardi 21 septembre 11h30 se tiendra uniquement sur TEAMS

Tuesday, September 21st, 2021 from 11:30 AM to 12:30 PM

Biopark Campus
Albert Claude Auditorium (Point Centre)
9 Avenue Georges Lemaître
6041 Gosselies (Belgium)